Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.

Reusch U, Harrington KH, Gudgeon CJ, Fucek I, Ellwanger K, Weichel M, Knackmuss SH, Zhukovsky EA, Fox JA, Kunkel LA, Guenot J, Walter RB.

Clin Cancer Res. 2016 Dec 1;22(23):5829-5838. Epub 2016 May 17.

2.

Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib.

Smith DD, Goldstein L, Cheng M, James DF, Kunkel LA, Fardis M, Hamdy A, Izumi R, Buggy JJ, Clow F.

Ann Hematol. 2015 Feb;94(2):249-56. doi: 10.1007/s00277-014-2187-9. Epub 2014 Sep 3.

PMID:
25178517
3.

Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.

Levy R, Ganjoo KN, Leonard JP, Vose JM, Flinn IW, Ambinder RF, Connors JM, Berinstein NL, Belch AR, Bartlett NL, Nichols C, Emmanouilides CE, Timmerman JM, Gregory SA, Link BK, Inwards DJ, Freedman AS, Matous JV, Robertson MJ, Kunkel LA, Ingolia DE, Gentles AJ, Liu CL, Tibshirani R, Alizadeh AA, Denney DW Jr.

J Clin Oncol. 2014 Jun 10;32(17):1797-803. doi: 10.1200/JCO.2012.43.9273. Epub 2014 May 5.

4.

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, Stilgenbauer S, Dreyling M, Jedrzejczak WW, Johnson P, Spurgeon SE, Li L, Zhang L, Newberry K, Ou Z, Cheng N, Fang B, McGreivy J, Clow F, Buggy JJ, Chang BY, Beaupre DM, Kunkel LA, Blum KA.

N Engl J Med. 2013 Aug 8;369(6):507-16. doi: 10.1056/NEJMoa1306220. Epub 2013 Jun 19.

5.

Phase Ib dose-escalation study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma.

Niesvizky R, Martin TG 3rd, Bensinger WI, Alsina M, Siegel DS, Kunkel LA, Wong AF, Lee S, Orlowski RZ, Wang M.

Clin Cancer Res. 2013 Apr 15;19(8):2248-56. doi: 10.1158/1078-0432.CCR-12-3352. Epub 2013 Feb 27.

6.

An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma.

Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, Somlo G, Bahlis N, Lonial S, Kunkel LA, Wong A, Orlowski RZ, Siegel DS.

Clin Lymphoma Myeloma Leuk. 2012 Oct;12(5):310-8. doi: 10.1016/j.clml.2012.08.003.

PMID:
23040437
7.

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.

Vij R, Siegel DS, Jagannath S, Jakubowiak AJ, Stewart AK, McDonagh K, Bahlis N, Belch A, Kunkel LA, Wear S, Wong AF, Wang M.

Br J Haematol. 2012 Sep;158(6):739-48. doi: 10.1111/j.1365-2141.2012.09232.x. Epub 2012 Jul 30.

8.

A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma.

Alsina M, Trudel S, Furman RR, Rosen PJ, O'Connor OA, Comenzo RL, Wong A, Kunkel LA, Molineaux CJ, Goy A.

Clin Cancer Res. 2012 Sep 1;18(17):4830-40. Epub 2012 Jul 3.

9.

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.

Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS.

Blood. 2012 Jun 14;119(24):5661-70. doi: 10.1182/blood-2012-03-414359. Epub 2012 May 3.

10.

Phase 1 experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinoma.

Burris HA 3rd, Rosen LS, Rocha-Lima CM, Marshall J, Jones S, Cohen RB, Kunkel LA, Loo D, Baughman J, Stewart SJ, Lewis N.

Clin Cancer Res. 2010 Mar 1;16(5):1673-81. doi: 10.1158/1078-0432.CCR-09-2263. Epub 2010 Feb 23.

11.

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.

O'Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF, Orlowski RZ.

Clin Cancer Res. 2009 Nov 15;15(22):7085-91. doi: 10.1158/1078-0432.CCR-09-0822. Epub 2009 Nov 10.

12.

Idiotype vaccines in the treatment of B-cell non-Hodgkin's lymphoma.

Kunkel LA.

Cancer Invest. 2004;22(1):97-105. Review. No abstract available.

PMID:
15069767
13.

Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma.

Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, Lowe A, Kunkel LA, Fisher RI.

J Clin Oncol. 2001 Jan 15;19(2):389-97.

PMID:
11208830
14.

Autologous transplantation of mobilized peripheral blood CD34+ cells selected by immunomagnetic procedures in patients with multiple myeloma.

Abonour R, Scott KM, Kunkel LA, Robertson MJ, Hromas R, Graves V, Lazaridis EN, Cripe L, Gharpure V, Traycoff CM, Mills B, Srour EF, Cornetta K.

Bone Marrow Transplant. 1998 Nov;22(10):957-63.

15.

CD34+ cell engraftment, ex vivo expansion, and malignant cell depletion following immunomagnetic selection.

Huntenburg CC, Kunkel LA, Schneidkraut MJ.

J Hematother. 1998 Apr;7(2):175-83.

PMID:
9597575
16.

Composition of peripheral blood progenitor cell components collected from healthy donors.

Stroncek DF, Clay ME, Smith J, Herr G, Ilstrup S, Kunkel LA, McCullough J.

Transfusion. 1997 Apr;37(4):411-7.

PMID:
9111279
17.

An association between renal cell carcinoma and lymphoid malignancies. A case series of eight patients.

Nishikubo CY, Kunkel LA, Figlin R, Belldegrun A, Rosen P, Elashoff R, Wang H, Territo MC.

Cancer. 1996 Dec 1;78(11):2421-6.

PMID:
8941014
18.

Production of anti-erythrocyte antibodies by leukemic and nonleukemic B cells in chronic lymphocytic leukemia patients.

Centola M, Lin K, Sutton C, Berenson JR, Kunkel LA, Rosen L, Hahn BH, Robinson RR.

Leuk Lymphoma. 1996 Feb;20(5-6):465-69.

PMID:
8833404
19.

Analysis of multiple myeloma third complementarity-determining regions reveals characteristics of prenatal B cells.

Kunkel LA, Vescio R, Cao J, Hong CH, Kim A, Schiller GJ, Lichtenstein AK, Berenson JR.

Ann N Y Acad Sci. 1995 Sep 29;764:519-22. No abstract available.

PMID:
7486579
21.

Acquired circulating anticoagulants.

Kunkel LA.

Hematol Oncol Clin North Am. 1992 Dec;6(6):1341-57. Review.

PMID:
1452516
22.

Disseminated intravascular coagulation syndromes.

Bick RL, Kunkel LA.

Int J Hematol. 1992 Feb;55(1):1-26. Review.

PMID:
1581579
23.

Acquired circulating anticoagulants in malignancy.

Kunkel LA.

Semin Thromb Hemost. 1992;18(4):416-23. Review. No abstract available.

PMID:
1470928
24.

Transient stress lymphocytosis during crisis of sickle cell anemia and emergency trauma and medical conditions. An immunophenotyping study.

Groom DA, Kunkel LA, Brynes RK, Parker JW, Johnson CS, Endres D.

Arch Pathol Lab Med. 1990 Jun;114(6):570-6.

PMID:
2095748
25.
26.

Interferon-mediated protection of normal and tumor target cells against lysis by mouse natural killer cells.

Welsh RM, Karre K, Hansson M, Kunkel LA, Kiessling RW.

J Immunol. 1981 Jan;126(1):219-25. No abstract available.

PMID:
6161162

Supplemental Content

Loading ...
Support Center